BRPI0414813A - método para o uso de bactéria que oxidam a amÈnia - Google Patents

método para o uso de bactéria que oxidam a amÈnia

Info

Publication number
BRPI0414813A
BRPI0414813A BRPI0414813-4A BRPI0414813A BRPI0414813A BR PI0414813 A BRPI0414813 A BR PI0414813A BR PI0414813 A BRPI0414813 A BR PI0414813A BR PI0414813 A BRPI0414813 A BR PI0414813A
Authority
BR
Brazil
Prior art keywords
oxidizing bacteria
ammonia
ammonia oxidizing
patient
bacteria
Prior art date
Application number
BRPI0414813-4A
Other languages
English (en)
Inventor
David R Whitlock
Original Assignee
David R Whitlock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David R Whitlock filed Critical David R Whitlock
Publication of BRPI0414813A publication Critical patent/BRPI0414813A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)

Abstract

"MéTODO PARA O USO DE BACTéRIA QUE OXIDAM A AMÈNIA". A presente invenção refere-se ao uso de bactérias que oxidam a amónia na fabricação de um medicamento e um método para tratar um paciente no qual se desenvolveu ou que esteja correndo o risco de desenvolver pelo menos uma das seguintes doenças: hipertensão, degeneração hipertrófica de órgão, fenómenos de Raynaud, degeneração fibrótica de órgão, alergias, sensibilização auto-imune, doença renal em fase final, obesidade, diabete tipo 1, osteoporose, impotência, perda de cabelo, câncer, envelhecimento, autismo, e sintomas do espectro do autismo, compreendendo a colocação das bactérias que oxidam a amónia em contato íntimo com uma superfície do corpo do paciente e a produção de óxido nítrico e de precursores do óxido nítrico pelo uso de bactérias que oxidam a amónia.
BRPI0414813-4A 2003-09-26 2004-09-27 método para o uso de bactéria que oxidam a amÈnia BRPI0414813A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50622503P 2003-09-26 2003-09-26
US58565204P 2004-07-06 2004-07-06
PCT/US2004/031690 WO2005030147A2 (en) 2003-09-26 2004-09-27 Methods of using ammonia oxidizing bacteria

Publications (1)

Publication Number Publication Date
BRPI0414813A true BRPI0414813A (pt) 2006-11-14

Family

ID=34396303

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414813-4A BRPI0414813A (pt) 2003-09-26 2004-09-27 método para o uso de bactéria que oxidam a amÈnia

Country Status (7)

Country Link
US (1) US20070148136A1 (pt)
EP (1) EP1667646A4 (pt)
JP (1) JP2007508247A (pt)
AU (1) AU2004275868A1 (pt)
BR (1) BRPI0414813A (pt)
CA (1) CA2539974A1 (pt)
WO (1) WO2005030147A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013982A1 (en) 2000-08-11 2002-02-21 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
TW200518825A (en) * 2003-11-14 2005-06-16 Babcock Hitachi Kk Method for apparatus for treating ammonia-containing gas
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
FI122718B (fi) * 2007-09-07 2012-06-15 Aalto Korkeakoulusaeaetioe Rasvan tuottaminen alkoholista
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN103074278B (zh) * 2012-12-28 2014-04-23 浙江至美环境科技有限公司 一种氨氧化细菌及其应用
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
AU2015247710B2 (en) 2014-04-15 2021-09-09 Aobiome Llc Ammonia-oxidizing Nitrosomonas eutropha strain D23
CN107429213B (zh) 2014-05-22 2022-01-14 Ao生物医学有限责任公司 储存和递送氨氧化细菌的系统和方法
CA2949833A1 (en) * 2014-05-22 2015-11-26 Aobiome Llc Methods of preparing materials with ammonia oxidizing bacteria and testing materials for ammonia oxidizing bacteria
JP2018524351A (ja) * 2015-07-02 2018-08-30 エーオーバイオーム， エルエルシー．ＡＯＢｉｏｍｅ， ＬＬＣ． ざ瘡の処置のためのアンモニア酸化細菌
BR112018000053A2 (pt) 2015-07-02 2018-09-04 Aobiome Llc cosméticos compatíveis com o microbioma
EP3487513A1 (en) * 2016-07-19 2019-05-29 Aobiome LLC Ammonia oxidizing microorganisms for use and delivery to the gastrointestinal system
CA3047041A1 (en) * 2016-12-12 2018-06-21 Aobiome Llc Ammonia oxidizing microorganisms for the regulation of blood pressure
WO2019018424A1 (en) * 2017-07-18 2019-01-24 Aobiome Llc MICROORGANISMS OXIDIZING AMMONIA FOR USE AND ADMINISTRATION TO THE VISUAL AND AUDITIVE SYSTEMS
WO2019191449A1 (en) * 2018-03-30 2019-10-03 Aobiome Llc Use and delivery of ammonia oxidizing microorganisms for treatment of neurodegenerative disorders
TW201943428A (zh) 2018-04-16 2019-11-16 大陸商上海岸闊醫藥科技有限公司 預防或治療腫瘤療法副作用的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2021530491A (ja) * 2018-07-11 2021-11-11 サイクレリオン・セラピューティクス，インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
US20240166988A1 (en) * 2021-03-31 2024-05-23 Jfr Co., Ltd. Nitrifying bacteria formulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055193A (en) * 1989-03-09 1991-10-08 Regents Of The University Of Minnesota Biodegradation of halogenated hydrocarbons utilizing ammonia-oxidizing bacterium
ES2132043T3 (es) * 1990-12-05 2008-04-01 The General Hospital Corporation Dispositivos para tratar vasoconstriccion pulmonar y asma.
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
DK0680346T3 (da) * 1992-02-07 2002-10-28 Vasogen Inc Fremgangsmåde til forøgelse af koncentrationen af nitrogenoxid i blod
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US6087479A (en) * 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9320978D0 (en) * 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
CA2175467A1 (en) * 1993-11-02 1995-05-11 David A. Wink, Jr. Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury
US5527825A (en) * 1994-04-06 1996-06-18 University Of Arkansas Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
ATE300308T1 (de) * 1994-12-12 2005-08-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5876603A (en) * 1995-08-10 1999-03-02 Hitachi Plant Engineering & Construction Co., Ltd. Method of biologically removing nitrogen and system therefor
US5849192A (en) * 1996-02-12 1998-12-15 Basf Corporation Procedure to recover from nitrification upsets
US5725492A (en) * 1996-03-04 1998-03-10 Cormedics Corp Extracorporeal circulation apparatus and method
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5765548A (en) * 1996-05-07 1998-06-16 Perry; Bryan J. Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5821112A (en) * 1996-10-04 1998-10-13 Botto; Willism S. Biological odor metabolizing compositions and methods of use
US5807546A (en) * 1996-10-11 1998-09-15 The United States Of America As Represented By The Secretary Of Agriculture Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria
US5958427A (en) * 1996-11-08 1999-09-28 Salzman; Andrew L. Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US20050036996A1 (en) * 1996-12-24 2005-02-17 Edmond Roussel Absorbable composition containing propionic bacteria capable of releasing nitric oxide in the human or animal alimentary canal
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
US5895658A (en) * 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6056966A (en) * 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
WO2002013982A1 (en) * 2000-08-11 2002-02-21 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
CA2473097A1 (en) * 2002-01-11 2003-07-17 David R. Whitlock Compositions including ammonia oxidizing bacteria and methods of using same

Also Published As

Publication number Publication date
WO2005030147A2 (en) 2005-04-07
EP1667646A2 (en) 2006-06-14
JP2007508247A (ja) 2007-04-05
EP1667646A4 (en) 2007-07-04
US20070148136A1 (en) 2007-06-28
CA2539974A1 (en) 2005-04-07
AU2004275868A1 (en) 2005-04-07
WO2005030147A3 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
BRPI0414813A (pt) método para o uso de bactéria que oxidam a amÈnia
BR0306868A (pt) Composições incluindo bactérias oxidando amonìaco e métodos para usar as mesmas
BRPI0417829A (pt) composições e processos para tratamento da diabetes
BRPI0410338A (pt) composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
BR0213377A (pt) mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas
ME00425B (me) Liječenje sa anti-vegf antitijelima
BRPI0509861A (pt) uso de simeticona em pacientes constipados
BRPI0409660A (pt) método de medida da eficiência de um programa de tratamento de pele
Shin et al. A survey on satisfaction for Korean medicine treatments in 237 traffic injury patients
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BRPI0418138A (pt) medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina
ATE282697T1 (de) Vektorkonstrukte zur gentherapeutisch vermittelten radionuklid-therapie entdifferenzierter und medullärer schilddrüsen- karzinome sowie nicht-thyreoidaler tumore und ihrer metastasen
Drobnik et al. The elements of specific biological activity in therapeutic waters in Polish health resorts.
Neerinckx et al. What happens to the fibromyalgia concept?
Cleaton-Jones Dental caries trends in 5 to 6 year-old and 11 to 13 year-old children in two UNICEF designated regions: Sub-Saharan Africa, and Middle East and North Africa, 1970-2000
BRPI0414153A (pt) agente para tingimento de fibras queratìnicas
DE60228945D1 (de) Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz
Ng et al. Idiopathic scleredema
BR0015329A (pt) Uso de óxido nìtrico para o tratamento de constrição das vias aéreas
Loost et al. Glutamine: a new anticystinuric drug?
Gupta et al. Application of community periodontal index of treatment need (CPITN) in a group of insulin dependent diabetes mellitus (IDDM) patients
KR200356200Y1 (ko) 반지의 구조
MD2327G2 (ro) Metodă de tratament al afecţiunilor parodonţiului
Jones et al. Haemoglobin A1c concentrations in men and women with diabetes.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.